FIELD: bioengineering.
SUBSTANCE: polypeptide with length below 100 aminoacids is suggested. The polypeptide contains sequence selected out of SEQ ID NO: 2, 3, 4, 7 or 8, or its immunogen fragment containing 8 aminoacids. The mixture of the polypeptides is suggested, it contains the first and the second polypeptides that differ from each other. Besides the pharmaceutical composition is suggested, it contains the above said polypeptide or mixture of the polypeptides. The method of medical treatment or preventive treatment of cancer is suggested with use of the said polypeptide, mixture of the polypeptides or the pharmaceutical composition.
EFFECT: group of inventions has increased immunogenicity during vaccination in comparison with the full-size protein hTERT, and ensures stimulation of T-cell immune response and increases duration of survival.
20 cl, 19 dwg, 10 tbl, 9 ex
